Vitmin B3.

The body makes part of its own niacin from tryptophan through the kynurenine pathway, at roughly sixty milligrams of tryptophan per milligram of niacin. Supplying niacin spares tryptophan for its other uses, including serotonin synthesis.

Kynurenine 3 monooxygenase is a flavin dependent enzyme, so the conversion of tryptophan into niacin stalls when riboflavin status is low. Riboflavin therefore sets how much of the pathway can run before dietary niacin has to cover the gap.

Kynureninase needs pyridoxal 5 phosphate to release the intermediate that goes on to form the nicotinamide ring. Low B6 status diverts the pathway and lowers how much niacin the body forms from tryptophan.

Nicotinamide is cleared by N methyltransferase, which spends a methyl group from S adenosylmethionine for each molecule handled. Larger B3 intakes therefore pull on the methyl pool, and betaine remethylates homocysteine back to methionine to refill it.

S adenosylmethionine is the direct methyl donor for nicotinamide N methyltransferase, so nicotinamide clearance draws on the same pool that methylation reactions elsewhere use. The two share one currency rather than acting independently.

The methyl groups spent clearing nicotinamide are restored through the folate cycle, where 5 methyltetrahydrofolate passes a methyl group to homocysteine. Folate status therefore sits upstream of how well the methyl pool keeps up.

Methionine synthase needs cobalamin to move a methyl group from folate onto homocysteine and regenerate methionine. That is the step that refills the methyl pool that nicotinamide clearance draws down.

Nicotinamide riboside and niacin both enter the same NAD pool, one through the nicotinamide riboside kinase route and the other through the Preiss Handler route. Stacking them adds precursor to one shared pool rather than to two separate ones.

NMN feeds the same NAD pool that niacin reaches by its own salvage route, converging at the final adenylylation step. The pairing raises one pool from two entry points.

Niacin exists in the body largely to build NAD, the hydride carrier for hundreds of dehydrogenase reactions. Supplying both a precursor and the dinucleotide acts on one pool, so the total intake is what counts.

The body can build a small share of its own niacin from tryptophan, and the first committed step runs through tryptophan 2,3-dioxygenase, a heme enzyme. Heme synthesis depends on iron, so poor iron status slows that conversion route. This is a cofactor relationship, not a claim that iron raises niacin status on its own.

NAD synthetase adds the amide group that turns nicotinic acid adenine dinucleotide into NAD, and in mammals glutamine is the nitrogen donor for that step. Glutamine is therefore part of the machinery that finishes NAD assembly from the nicotinic acid branch. The relationship is biochemical rather than a tested supplement pairing.

NAD salvage runs through phosphoribosyl pyrophosphate, a ribose-derived donor that couples to the nicotinamide or nicotinic acid ring. Ribose feeds the pentose phosphate pool that supplies that donor. The link is upstream chemistry; no combination trial is being described here.

NAD kinase phosphorylates NAD to NADP using ATP, and ATP is handled as a magnesium complex. Magnesium is also required across the kinases that keep the adenine nucleotide pool moving. Adequate magnesium status is part of normal NADP turnover.

NADH generated by B3-dependent dehydrogenases hands its electrons to complex I, which passes them to coenzyme Q10 in the inner mitochondrial membrane. The two sit one step apart on the same electron route. This describes normal energy metabolism, not an effect measured for the pair.

Electrons entering the chain as NADH leave it at cytochrome c oxidase, a copper-containing complex. Copper status therefore sits at the far end of the same pathway that B3 supplies at the near end. The connection is structural to the pathway rather than a supplementation finding.

Glutathione reductase regenerates reduced glutathione using NADPH, which derives from the NADP pool that B3 supplies. Without NADPH the recycling step stalls and glutathione stays oxidised. This is settled redox biochemistry.

N-acetylcysteine supplies cysteine for glutathione synthesis, while the NADPH derived from the NADP pool keeps that glutathione in its reduced state. The two act on different halves of the same cycle, one on supply and one on regeneration.

Selenium-dependent glutathione peroxidases and thioredoxin reductase both depend on NADPH-driven regeneration to keep working through repeated cycles. B3 supplies the NADP backbone for that reducing power. The pairing describes normal antioxidant enzyme turnover.

Alcohol dehydrogenase and several aldehyde dehydrogenases are zinc metalloenzymes that use NAD as their electron acceptor. Zinc holds the catalytic site, B3 supplies the cosubstrate. Neither substitutes for the other.

Lipoic acid sits in the E2 core of the pyruvate and alpha-ketoglutarate dehydrogenase complexes, and the E3 subunit that resets it is a flavoprotein that passes electrons to NAD. The complex needs both the lipoyl arm and the NAD acceptor to turn over. This is textbook cofactor architecture.

Excess nicotinamide is cleared by nicotinamide N-methyltransferase, which spends a methyl group from S-adenosylmethionine on every molecule it clears. Choline, through betaine, is one of the routes that refills that methyl pool. High B3 intake is a draw on methyl supply rather than a partner to it, which is why the two are worth reading together.

S-adenosylmethionine is made from methionine, and methylation of nicotinamide consumes it. Sustained high nicotinamide intake therefore competes with other methyltransferase reactions for the same donor. The direction of the interaction is a demand on methionine, not a boost to it.

Glycine N-methyltransferase is the main buffer that disposes of surplus S-adenosylmethionine, and nicotinamide methylation draws on the same donor pool. The two reactions share one currency. Read the relationship as competition for methyl groups rather than a combined benefit.

CD38 is a major NAD-consuming enzyme, and quercetin inhibits it in laboratory work. Slower consumption alongside precursor supply is the mechanistic rationale for pairing them. The evidence here is preclinical and describes enzyme activity, not a measured human outcome.

Apigenin inhibits CD38 in cell and animal work, which slows the degradation side of NAD turnover. B3 works on the supply side. The pairing is mechanistic and has not been demonstrated as a clinical effect in people.

Sirtuins cleave NAD as part of every deacetylation cycle, so their activity depends on NAD availability. Resveratrol is studied as a sirtuin-pathway modulator and B3 supplies the cosubstrate those enzymes spend. The shared dependency is the basis; combined clinical outcomes are not established.

Dehydroascorbate is reduced back to ascorbate by systems that draw on NADH and NADPH-dependent reductases as well as glutathione. The NAD pool therefore sits behind part of ascorbate recycling. This is enzyme-level chemistry, not a demonstrated additive effect in people.